Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Rating Lowered by Wall Street Zen

Zentalis Pharmaceuticals (NASDAQ:ZNTL) was downgraded by research analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Saturday.

Other equities analysts have also recently issued reports about the company. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday, May 22nd. Mizuho initiated coverage on shares of Zentalis Pharmaceuticals in a research report on Friday, July 17th. They set an “outperform” rating and a $8.00 price target on the stock. Guggenheim lifted their price target on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, April 10th. Rodman & Renshaw began coverage on shares of Zentalis Pharmaceuticals in a report on Thursday, July 23rd. They issued a “buy” rating and a $11.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Monday, July 6th. Four research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Zentalis Pharmaceuticals has an average rating of “Hold” and an average price target of $6.75.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ:ZNTL opened at $4.22 on Friday. The firm has a market capitalization of $302.45 million, a PE ratio of -2.16 and a beta of 1.92. Zentalis Pharmaceuticals has a 52-week low of $1.21 and a 52-week high of $6.95. The firm has a fifty day moving average of $4.31 and a 200 day moving average of $3.60.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). On average, sell-side analysts forecast that Zentalis Pharmaceuticals will post -1.83 EPS for the current fiscal year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC lifted its position in Zentalis Pharmaceuticals by 177.6% in the first quarter. AQR Capital Management LLC now owns 619,330 shares of the company’s stock valued at $985,000 after purchasing an additional 396,233 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Zentalis Pharmaceuticals by 220.6% in the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock worth $4,881,000 after purchasing an additional 2,111,951 shares during the last quarter. Qube Research & Technologies Ltd purchased a new position in shares of Zentalis Pharmaceuticals in the second quarter worth $37,000. Sei Investments Co. increased its stake in shares of Zentalis Pharmaceuticals by 373.1% in the second quarter. Sei Investments Co. now owns 167,100 shares of the company’s stock worth $194,000 after buying an additional 131,780 shares during the period. Finally, Jane Street Group LLC raised its holdings in Zentalis Pharmaceuticals by 346.3% during the 2nd quarter. Jane Street Group LLC now owns 664,061 shares of the company’s stock valued at $770,000 after buying an additional 515,257 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.